Stage III Renal Cell Cancer Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0028847 (Stage III Renal Cell Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03229278Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaTreatment